Baseline requirements for novel agents being considered for phase II/III brain cancer efficacy trials: conclusions from the Adult Brain Tumor Consortium’s first workshop on CNS drug delivery
Neuro-Oncology | June 2, 2020 | Volume: 22 | Issue: 10 | Pages: 1422-1424
10.1093/neuonc/noaa142
| PMID 32506123